Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROSPERO extension study of tozorakimab in symptomatic COPD
jRCT2031220659Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Mar 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial of tozorakimab in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by AstraZeneca. Primary endpoint: Annualised rate of severe COPD exacerbations in former smokers. Started Mar 2023; status: completed.
02
Drugs
tozorakimab
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on jRCT2031220659.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220659.